These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34952995)

  • 1. Multicenter, randomized, double-blinded, placebo-controlled study of rabacfosadine in dogs with lymphoma.
    Weishaar KM; Wright ZM; Rosenberg MP; Post GS; McDaniel JA; Clifford CA; Phillips BS; Bergman PJ; Randall EK; Avery AC; Thamm DH; Christman Hull AA; Gust CM; Donoghue AR
    J Vet Intern Med; 2022 Jan; 36(1):215-226. PubMed ID: 34952995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs.
    Cawley JR; Wright ZM; Meleo K; Post GS; Clifford CA; Vickery KR; Vail DM; Bergman PJ; Thamm DH
    J Vet Intern Med; 2020 Mar; 34(2):882-889. PubMed ID: 32064697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma.
    Thamm DH; Vail DM; Post GS; Fan TM; Phillips BS; Axiak-Bechtel S; Elmslie RS; Klein MK; Ruslander DA
    J Vet Intern Med; 2017 May; 31(3):872-878. PubMed ID: 28370378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternating rabacfosadine and doxorubicin for treatment of naïve canine lymphoma.
    Saba CF; Fan TM; Phillips BS; Wright ZM; Thamm DH
    Vet Comp Oncol; 2024 Jun; 22(2):278-283. PubMed ID: 38616055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials.
    Saba CF; Clifford C; Burgess K; Phillips B; Vail D; Wright Z; Curran K; Fan T; Elmslie R; Post G; Thamm D
    Vet Comp Oncol; 2020 Dec; 18(4):763-769. PubMed ID: 32346934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses.
    Saba CF; Vickery KR; Clifford CA; Burgess KE; Phillips B; Vail DM; Wright ZM; Morges MA; Fan TM; Thamm DH
    Vet Comp Oncol; 2018 Mar; 16(1):E76-E82. PubMed ID: 28891260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early progression during or after cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy indicates poor outcome with rescue protocols in dogs with multicentric lymphoma.
    Parker AS; Burton JH; Curran KM; Wolf-Ringwall A; Thamm DH
    J Vet Intern Med; 2024; 38(4):2282-2292. PubMed ID: 38961691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma.
    Morges MA; Burton JH; Saba CF; Vail DM; Burgess KE; Thamm DH
    J Vet Intern Med; 2014; 28(5):1569-74. PubMed ID: 25274443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tanovea® for the treatment of lymphoma in dogs.
    De Clercq E
    Biochem Pharmacol; 2018 Aug; 154():265-269. PubMed ID: 29778492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinblastine as a second rescue for the treatment of canine multicentric lymphoma in 39 cases (2005 to 2014).
    Lenz JA; Robat CS; Stein TJ
    J Small Anim Pract; 2016 Aug; 57(8):429-34. PubMed ID: 27251593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study.
    Lori JC; Stein TJ; Thamm DH
    Vet Comp Oncol; 2010 Sep; 8(3):188-95. PubMed ID: 20691026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma.
    Burton JH; Garrett-Mayer E; Thamm DH
    Vet Comp Oncol; 2013 Dec; 11(4):306-15. PubMed ID: 22548975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma.
    Parsons-Doherty M; Poirier VJ; Monteith G
    Can Vet J; 2014 Feb; 55(2):175-80. PubMed ID: 24489398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy with continuous L-asparaginase, lomustine, and prednisone for relapsed canine lymphoma.
    Saba CF; Hafeman SD; Vail DM; Thamm DH
    J Vet Intern Med; 2009; 23(5):1058-63. PubMed ID: 19678892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma.
    Alvarez FJ; Kisseberth WC; Gallant SL; Couto CG
    J Vet Intern Med; 2006; 20(5):1178-83. PubMed ID: 17063713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dacarbazine as single-agent therapy for relapsed lymphoma in dogs.
    Griessmayr PC; Payne SE; Winter JE; Barber LG; Shofer FS
    J Vet Intern Med; 2009; 23(6):1227-31. PubMed ID: 19709354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol.
    Curran K; Thamm DH
    Vet Comp Oncol; 2016 Aug; 14 Suppl 1():147-55. PubMed ID: 26279153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma.
    Saba CF; Thamm DH; Vail DM
    J Vet Intern Med; 2007; 21(1):127-32. PubMed ID: 17338160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asparaginase and MOPP treatment of dogs with lymphoma.
    Brodsky EM; Maudlin GN; Lachowicz JL; Post GS
    J Vet Intern Med; 2009; 23(3):578-84. PubMed ID: 19645842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide alone or in combination with doxorubicin as a rescue agent in 37 cases of canine multicentric lymphoma.
    Treggiari E; Elliott JW; Baines SJ; Blackwood L
    Vet Comp Oncol; 2018 Jun; 16(2):194-201. PubMed ID: 28766920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.